Tue, Jul 22, 2014, 10:54 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • naked_finger naked_finger Jul 31, 2013 12:38 AM Flag

    Synta Pharmaceuticals Corp. Given New $20.00 Price Target at Roth Capital (SNTA)

    Equities research analysts at Roth Capital lifted their price target on shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) from $18.00 to $20.00 in a research note issued to investors on Tuesday,

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The firm currently has a “buy” rating on the stock. Roth Capital’s target price indicates a potential upside of 193.69% from the company’s current price.

      Several other analysts have also recently commented on the stock. Analysts at JMP Securities upgraded shares of Synta Pharmaceuticals Corp. from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday, July 16th. They now have a $11.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Synta Pharmaceuticals Corp. in a research note to investors on Tuesday, July 2nd. They now have a $22.00 price target on the stock. Finally, analysts at MLV Capital cut their price target on shares of Synta Pharmaceuticals Corp. from $18.50 to $16.00 in a research note to investors on Thursday, June 6th. They now have a “buy” rating on the stock.

      Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Synta Pharmaceuticals Corp. has an average rating of “Buy” and a consensus price target of $16.20.

    • Shorts, Soil ur brown pants. Haha

 
SNTA
4.15+0.08(+1.97%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.